<DOC>
	<DOCNO>NCT02438007</DOCNO>
	<brief_summary>The purpose study compare galeterone enzalutamide men express androgen receptor spice variant-7 mRNA ( AR-V7 ) metastatic ( M1 ) castrate resistant prostate cancer ( CRPC ) .</brief_summary>
	<brief_title>A Study Galeterone Compared Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA ( AR-V7 ) Metastatic CRPC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Progressive metastatic ( M1 ) disease androgen deprivation therapy Detectable ARV7 circulate tumor ( CTCs ) ECOG performance status 0 1 Prior treatment second generation antiandrogens ( e.g . abiraterone , enzalutamide ) Prior treatment chemotherapy CRPC</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>